Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

5274 ARTÍCULOS , VIENDO DEL 3556 AL 3570

What did we learn from neural grafts in Huntington disease?

Bachoud-Lévi AC.

Rev Neurol (Paris). 2022 May;178(5):441-449. doi: 10.1016/j.neurol.2022.03.004. Epub 2022 Apr 28.

Disordered Decision Making: A Cognitive Framework for Apathy and Impulsivity in Huntington's Disease

Morris LA, O'Callaghan C, Le Heron C.

Mov Disord. 2022 Jun;37(6):1149-1163. doi: 10.1002/mds.29013. Epub 2022 May 2.

Recent Trends and Practices Toward Assessment and Rehabilitation of Neurodegenerative Disorders: Insights From Human Gait

Das R, Paul S, Mourya GK, Kumar N, Hussain M.

Front Neurosci. 2022 Apr 15;16:859298. doi: 10.3389/fnins.2022.859298. eCollection 2022.

Altered Cholesterol Homeostasis in Huntington's Disease

Kacher R, Mounier C, Caboche J, Betuing S.

Front Aging Neurosci. 2022 Apr 19;14:797220. doi: 10.3389/fnagi.2022.797220. eCollection 2022.

Cytoskeleton saga: Its regulation in normal physiology and modulation in neurodegenerative disorders

Sen S, Lagas S, Roy A, Kumar H.

Eur J Pharmacol. 2022 Jun 15;925:175001. doi: 10.1016/j.ejphar.2022.175001. Epub 2022 May 4.

Emerging roles of extracellular vesicles in polyglutamine diseases: Mutant protein transmission, therapeutic potential, and diagnostics

Takeuchi T, Nagai Y.

Neurochem Int. 2022 Jul;157:105357. doi: 10.1016/j.neuint.2022.105357. Epub 2022 May 4.

Cysteine metabolism and hydrogen sulfide signaling in Huntington's disease

Paul BD.

Free Radic Biol Med. 2022 Jun;186:93-98. doi: 10.1016/j.freeradbiomed.2022.05.005. Epub 2022 May 10.

MicroRNA Alteration, Application as Biomarkers, and Therapeutic Approaches in Neurodegenerative Diseases

Nguyen TPN, Kumar M, Fedele E, Bonanno G, Bonifacino T.

Int J Mol Sci. 2022 Apr 25;23(9):4718. doi: 10.3390/ijms23094718.

Yeast as a Model to Find New Drugs and Drug Targets for VPS13-Dependent Neurodegenerative Diseases

Kaminska J, Soczewka P, Rzepnikowska W, Zoladek T.

Int J Mol Sci. 2022 May 4;23(9):5106. doi: 10.3390/ijms23095106.

RhoA Signaling in Neurodegenerative Diseases

Schmidt SI, Blaabjerg M, Freude K, Meyer M.

Cells. 2022 May 1;11(9):1520. doi: 10.3390/cells11091520.

Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation

Kasindi A, Fuchs DT, Koronyo Y, Rentsendorj A, Black KL, Koronyo-Hamaoui M.

Cells. 2022 May 7;11(9):1578. doi: 10.3390/cells11091578.

Predicting clinical scores in Huntington's disease: a lightweight speech test

Riad R, Lunven M, Titeux H, Cao XN, Hamet Bagnou J, Lemoine L, Montillot J, Sliwinski A, Youssov K, Cleret de Langavant L, Dupoux E, Bachoud-Lévi AC.

J Neurol. 2022 Sep;269(9):5008-5021. doi: 10.1007/s00415-022-11148-1. Epub 2022 May 14.

Dimethyl fumarate: A review of preclinical efficacy in models of neurodegenerative diseases

Majkutewicz I.

Eur J Pharmacol. 2022 Jul 5;926:175025. doi: 10.1016/j.ejphar.2022.175025. Epub 2022 May 13.

Antiphospholipid-Related Chorea: Two Case Reports and Role of Metabolic Imaging

Lerjefors L, Andretta S, Bonato G, Mainardi M, Carecchio M, Antonini A.

Mov Disord Clin Pract. 2022 Mar 28;9(4):516-521. doi: 10.1002/mdc3.13432. eCollection 2022 May.

Dual phase (18)F-FP CIT PET and (99m)Tc- ECD SPECT findings of Huntington's disease

Chun K.

Radiol Case Rep. 2022 May 9;17(7):2460-2463. doi: 10.1016/j.radcr.2022.03.109. eCollection 2022 Jul.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias